Determination of phenotypical and biological characteristics of mesenchymal stem cells in pediatric myelodysplastic syndromes

Determination of phenotypical and biological characteristics of mesenchymal stem cells in pediatric myelodysplastic syndromes - MSC's in children with MDS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31742

Enrollment

Registered

2008-08-07

Start date

2009-01-29

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndroom op het kinderleeftijd bone marrow dysfunction pre-leukemia

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Patient inclusion criteria 1 Children aged 0-18 years. 2 Patients enrolled in EWOG-MDS/JMML 2006 study. 3 Informed written consent. Study control inclusion criteria 1 Normal fully screened donor undergoing bone marrow harvest. 2 Sufficient cells for marrow recipient. 3 Pediatric patients with de novo ANLL 4 Informed written consent.

Exclusion criteria

Exclusion criteria: Patient exclusion criteria 1 Failure of bone marrow aspirate. 2 Failure of MSC expansion;Donor control exclusion criteria 1 Insufficient harvest (cell dose below target). 2 Failure of MSC expansion.

Design outcomes

Primary

Measure	Time frame
1. Determination for each patient and control the phenotypical and biological characteristics of MSCs by flow cytometric analysis, cell culture and differentiation abilities. 2. Determination of functional characteristics of MSC's isolated from pediatric MDS patients and controls: - immune regulation of T and NK cell function - cytokine and growth factor expression of MSCs and the expression of chemokine receptor profiles 3. Determination of cytogenetic abnormalities of MSCs and HSCs in MDS patients and controls. 4. Determination of cell cycle control, apoptosis and differentiation by gene array of MSCs and HSCs from children with MDS and controls. 5. Determination of MSC and CD34+ve HSC*s from MDS patients to support normal hematopoiesis compared to controls.	—

Measure

Time frame

1. Determination for each patient and control the phenotypical and biological characteristics of MSC*s by flow cytometric analysis, cell culture and differentiation abilities. 2. Determination of functional characteristics of MSC's isolated from pediatric MDS patients and controls: - immune regulation of T and NK cell function - cytokine and growth factor expression of MSC*s and the expression of chemokine receptor profiles 3. Determination of cytogenetic abnormalities of MSC*s and HSC*s in MDS patients and controls. 4. Determination of cell cycle control, apoptosis and differentiation by gene array of MSC*s and HSC*s from children with MDS and controls. 5. Determination of MSC and CD34+ve HSC*s from MDS patients to support normal hematopoiesis compared to controls.

—

Countries

Netherlands

Outcome results